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Edited by Berend WieringaAbstract This study focused on the stability of UCP2 (uncou-
pling protein 2), a mitochondrial carrier located in the inner
membrane of mitochondrion. UCP2 is very unstable, with a
half-life close to 30 min, compared to 30 h for its homologue
UCP1, a diﬀerence that may highlight diﬀerent physiological
functions. Heat production by UCP1 in brown adipocytes is gen-
erally a long and adaptive phenomenon, whereas control of mito-
chondrial ROS by UCP2 needs more subtle regulation. We show
that a mutation in UCP2 shown to modify its activity, actually
decreases its stability.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The uncoupling proteins (UCPs) belong to the family of
mitochondrial carriers located in the inner membrane. UCP1
is speciﬁcally expressed in brown adipocytes, and acts as a pro-
ton carrier in uncoupling oxidative phosphorylation [1,2],
thereby ensuring the non-shivering thermogenesis of brown
adipose tissue [3,4].
UCP1 and its ﬁrst homologue, UCP2 [5], share 59% homol-
ogy, but in many respects. First, UCP1 is involved in non-shiv-
ering thermogenesis, whereas UCP2 plays no role in
thermogenesis [6]. Second, whereas UCP1 is speciﬁcally ex-
pressed in brown adipose tissue, UCP2 is expressed in many
tissues, such as spleen, lung, intestine, pancreatic b cells, and
immune cells [7–9]. Third, UCP1 expression is transcription-
ally regulated, whereas UCP2 protein level can change without
any alteration in mRNA level [7].
Several physiological situations highlight the importance of
regulation for UCP2 expression, since UCP2 protein level in-
creases and decreases in a very short time. LPS injection in
mice leads to rapid downregulation of UCP2 protein in macro-
phages, whereas its expression increases strongly and tran-
siently in the lung 16 hours after LPS injection [6,7,10,11].*Corresponding author. Present address: INSERM, U764, Clamart,
F-92140, France. Fax: +33 1 46 32 79 93.
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ovary and uterus [12] or during kainic acid-induced seizure
in neurons [13]. Taken together, these data suggest the exis-
tence of protein regulation, allowing a rapid decrease in
UCP2 expression, while translational regulation accounts for
the rapid increase in UCP2 expression. These results suggested
that UCP2 is very less stable than its homologue UCP1 since
Puigserver et al. described that the half-life of UCP1 was very
long from 20 to 30 h [14]. We show here that the half-life of
UCP2 is short, approximately 30 min, compared with about
30 h for UCP1 [14]. We also investigated the eﬀect on UCP2
half-life of three polymorphic sites in the translated region
[15,16], and of the dominant negative D212N mutation [17].2. Materials and methods
2.1. Plasmids and mutagenesis
A pYeDP plasmid containing human UCP2 was used [18]. Muta-
genesis was done using the QuikChange multisite-directed mutagenesis
kit (Stratagen). All clones were sequenced to conﬁrm the targeted
mutations. Oligonucleotide sequences were as follows:
C/T 164:: A55V 50 GTGCGCGCTACAGTCAGCGCCCAGTACCGC
G/A 253:: G85S 50 GGTTGCCAGCCTGCAGCGCCAAATGAGCTT
G/A 634:: D212N 50 AAAGCCAACCTCATGACAAATGACCTCCCT
G/A 694:: A232T 50 ACCACTGTCATCACCTCCCCTGTAGACGTG
2.2. Yeast culture, electroporation and half-life analysis
The W303 strain was transformed by electroporation as described
previously [19], with pYeDP plasmid containing UCP1, UCP2 or each
of the mutated UCP2 clones. After 3–4 days of growth on a selected
medium at 30 C, colonies were seeded in a minimum medium without
uracil until OD = 0.5. Galactose (0.1%) was added for 2 h in the ab-
sence of glucose to induce the UCP promoter. Galactose was removed,
and a sample was taken for the ﬁrst point of the time course. Cyclohex-
imide (100 lg/ml) was added to the rest of the culture. The time course
was recorded from 30 min to 24 h.2.3. Cell culture and treatments
Stable CHO cells expressing UCP2 were obtained as previously de-
scribed for UCP1 [20] and were cultured in Ham/F12 medium supple-
mented with 10% foetal calf serum (FCS). Caco-2 (from Dr. E.
Laroche) and POGRS-1 (from Dr. A. Amterdam) cell lines were
grown in DMEM/F12 supplemented with 10% FCS and 2 mM gluta-
mine. Nonessential amino acids (1 mM) were added to Caco-2 culture.
All media contained penicillin (100 IU/ml) and streptomycin (50 lg/
mL). Cell lines were grown in a humidiﬁed atmosphere of 5% CO2
and 37 C. To determine UCP half-life, cells were treated with cyclo-
heximide (10 lg/ml). The time course was recorded from 0 to 24 h.2.4. Animals and treatment
Studies on mice were performed in agreement with the institu-
tional CNRS guidelines deﬁned by the European Community guidingblished by Elsevier B.V. All rights reserved.
480 S. Rousset et al. / FEBS Letters 581 (2007) 479–482principles, and by French decree No. 87/848. C57BL/6 J mice (Elevage
Janvier) were maintained under a 12-h light, 12-h dark schedule, with
food and water ad libitum. Mice were injected with cycloheximide
(2 mg/kg) and sacriﬁced by cervical dislocation. Tissues were removed
and kept at 20 C until protein extraction.
2.5. Western blot analysis
Mitochondrial proteins were prepared from cells, tissues or yeasts as
described [7,19]. In Western blots [7], membranes were hybridised with
appropriate antibodies as previously published: UCP2, hUCP2-605
antibody [7], UCP1, 375-5 antibody [21]. In each experiment, the
amounts of UCP1 and UCP2 were normalized by using an antibody
against porin. Chemiluminescence (ECL kit, Amersham) was recorded
using a CCD camera.3. Results
3.1. Half-life of UCP1 and UCP2 in mammalian cells
The half-life of UCP2 was measured in two cell lines endog-
enously expressing UCP2, Caco-2, a human colon carcinoma
cell line and POGRS-1, a granulosa cell line. We also used a
stable CHO clone expressing UCP2 heterogeneously. Fig. 1A
shows the kinetics of degradation of UCP2 in these cells after
treatment with cycloheximide, a translation inhibitor. Interest-
ingly, 25 min after the treatment, UCP2 expression was al-
ready decreased by 50%. Similar experiments in CHO cells
with UCP1 showed a half-life close to 30 h (data not shown),
as previously described [14]. UCP2 half-life was also measured
in vivo. After injection of cycloheximide in C57BL/6 J mice,
UCP2 was assayed in spleen, lung and duodenum. In agree-
ment with our in vitro studies, UCP2 rapidly decreased inFig. 1. Half-life of UCP2 in vitro and in vivo: (A) Cell lines (CHO
n = 2, Caco-2 n = 4 and POGRS1 n = 6) were treated with cyclohex-
imide (10 lg/ml). UCP2 level was determined by Western blot analysis
with 30 lg of proteins. (B) Mice were injected i.p. with cycloheximide
(2 mg/kg). Tissues were removed 1 and 2 h later. 15 lg were loaded
onto polyacrylamide gel (n = 2 with three animals for each time point).the three organs tested (Fig. 1B). These data agree with previ-
ous descriptions of rapid variations in UCP2 level in tissues
[7,12].
3.2. Half-life of UCPs and UCP2 mutant proteins in yeast
We analysed whether a mutation in its sequence could mod-
ify UCP2 stability. To avoid the establishment of stable cell
line expressing each mutant, we chose the yeast Saccharomyces
cerevisiae since previous studies have shown that yeast is a rel-
evant model to analyse UCPs function [22].
In this heterologous system, the half-life of UCP2 was calcu-
lated to be around 60 min (Fig. 2A), conﬁrming the results ob-
tained in mammalian cells and mammalian tissues. We tested
the eﬀect of three polymorphisms in the coding region of
human UCP2, A55V, G85S and A232T. No signiﬁcant diﬀer-
ences were observed in the half-life of these isoforms compared
to the wild-type UCP2 (Fig. 2B). A UCP2 mutant protein,Fig. 2. Half-life of UCP2 and modiﬁed UCP2 in yeast: the kinetics of
degradation of UCPs in the yeast Saccharomyces cerevisiae was
recorded as described in Section 2. (A) UCP expression was analysed
by Western blot with 15 lg of proteins (n = 5). (B) Histograms
represent the half-life determined for each UCP2 form (n = 3).
*P < 0.05.
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half-life than wild-type UCP2 (Fig. 2B).4. Discussion
UCP2 has a shorter half-life (around 30 min) than its UCP1
homologue (30 h) [12]. Degradation of mitochondrial proteins
in the inner membrane is controlled by the AAA proteases
(ATPases Associated with a variety of cellular Activities)
[23], which have been largely studied in yeast. To investigate
the role of these proteases in the half-life of UCPs, we tested
the stability of UCP1 and UCP2 in wild-type and mutant
yeasts. We ﬁrst ruled out degradation by the proteasome, since
addition of inhibitor of this pathway does not modify UCP
half-life. We then tested involvement of the iAAA protease
(yme1) and the mAAA proteases (afg3 and rca1) by using
yeast since it was described mammal proteases are able to re-
store degradation function of protease disruptant yeast
[24,25]. However, whatever the protease mutant used, the
half-life of UCP1, as well as UCP2, remained unchanged (data
not shown), so these proteases are not involved in UCP degra-
dation. Two recently reported proteases, Oma1 [26] or
Mop112 [27], or as yet unknown proteases, may be involved
in proteolysis of UCP1 and UCP2.
The diﬀerence in UCP half-lives may be related to their dif-
ferent physiological functions. Cold-induced thermogenesis
due to UCP1 activity in brown adipocytes is generally not
transient, and, therefore, it is important for UCP1 to be ex-
pressed at a high level over a long period of time. In contrast,
UCP2 is present in many tissues whose role is not to produce
heat. UCP2 is implicated in the immune response by regulating
ROS production [6,11,28]. After infection by a pathogen, the
ROS pathway plays an important role leading to activation
of macrophages and other immune cells that eliminate the
pathogen. However, this ROS production must not last if tis-
sue damage is to be avoided. Moreover, during the oestrus cy-
cle in females, UCP2 rapidly decreases to allow the production
of ROS [12]. This event is necessary to oocyte release, but must
be strictly regulated in order to avoid side eﬀects, such as a
destruction of the oocyte. The regulation of ROS level must
be subtle, and it is clear that UCP2, as a regulator of ROS le-
vel, is both rapidly synthesised and degraded.
The UCP2 half-life measured here is short and unusual.
Although the half-lives of mitochondrial carriers have not of-
ten been investigated, it is accepted that they are over 10 h.
Few data are available, but the half life of P450cc (cholesterol
side chain cleavage cytochrome P450), an inner membrane
mitochondrial protein, is around 20 h [29].
We analysed variations in UCP2 half-life using known
mutations. For the three known polymorphisms already de-
scribed, a slight, but not signiﬁcant, decrease in half-life was
observed. For the D212N mutation, UCP2 half-life was signif-
icantly reduced by 60%. Mills et al. demonstrated that the
D212N mutation led to an increase in the mitochondrial mem-
brane potential [17], suggesting that this mutation was impair-
ing UCP2 activity. Our data imply that the reported decreased
activity of the D212 mutation should, in fact, be explained by a
decreased stability of the mutant. The absence of UCP2 in
mice promotes atherosclerosis [28], chronic inﬂammatory dis-
eases like experimental autoimmune encephalomyelitis [30],
and cancers [31], and the search for D212N polymorphic siteassociations with such diseases in appropriate cohorts of pa-
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